Mackay Shields LLC’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Mackay Shields LLC’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-24,009	Closed	-$2.33M	–	1522
2019 Q3	$2.33M	Sell	24,009 -1,400	-6%	-$140K	0.01%	844
2019 Q2	$2.6M	Buy	25,409 +16,387	+182%	+$1.77M	0.02%	794
2019 Q1	$1.03M	Sell	9,022 -3,300	-27%	-$243K	0.01%	989
2018 Q4	$482K	Buy	12,322 +633	+5%	+$27.5K	﹤0.01%	1151
2018 Q3	$638K	Buy	11,689 +1,400	+14%	+$95.7K	﹤0.01%	966
2018 Q2	$851K	Sell	10,289 -1,400	-12%	-$108K	0.01%	999
2018 Q1	$778K	Buy	+11,689	New	+$675K	﹤0.01%	1036

Mackay Shields LLC's ONCE Position: Q4 2019 in Review

Mackay Shields LLC sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 24,009 shares — an estimated $2.33M sold.

Mackay Shields LLC first reported a position in ONCE in Q1 2018 and held it in 7 quarters. The position peaked at $2.6M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

Mackay Shields LLC reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Mackay Shields LLC sold 24,009 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $2.33M.
Mackay Shields LLC first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Mackay Shields LLC's Spark Therapeutics, Inc. Common Stock position peaked at $2.6M in Q2 2019.
0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Mackay Shields LLC's 13F filing for Q4 2019, filed 11 Feb 2020.